Organon Canada Inc.
15 meetings with public office holders, Sep 8, 2025 to Feb 25, 2026.
28 meetings on record since 2023, their first on record.
Meetings over time
- Sep 2025: 2 meetings, with Manuela Tomic, Mélanie Joly
- Oct 2025: 0 meetings
- Nov 2025: 10 meetings, with Danièle Henkel, Krista Ross, Mary Robinson, Ian Cameron, Manuela Tomic
- Dec 2025: 0 meetings
- Jan 2026: 0 meetings
- Feb 2026: 3 meetings, with Pamela Aung-Thin, Danièle Henkel
Sep 2025peak 10 in a monthFeb 2026
Hover or focus a month to see who was met.
What they lobby about
The registry's own subject categories, chosen by the lobbyist on each filing. Each one opens its own page.
Who they met
Liberal2 met · 2 meetings
Senators2 met · 4 meetings
Bloc1 met · 2 meetings
Conservative1 met · 2 meetings
Not in Arena's member list12 met · 14 meetings
- Manuela Tomic
- Mary Robinson
- Adrian Deleanu
- Ian Cameron
- Kara Emberson
- Krista Ann Ross
- Krista Ross
- Mehek Noorani
- Pamela Aung-Thin
- Pavlo Kucher
- Shahad Khalladi
- Vincent Desmarais
Senate of Canada (9) · House of Commons (8) · Innovation, Science and Economic Development Canada (ISED) (4) · Health Canada (HC) (3)
In their own words
- Representations relating to the conditions under which biosimilar drugs are marketed and reimbursed in Canada. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current women’s health programs, the integration of biosimilar drugs into the drug plans administered by the Federal Government and to emphasize the importance that the federal government respect their respective jurisdiction with respect to the approval, marketing and reimbursement of Organon's products.
- Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities.
- To advocate for the adoption of Bill S-243 ("An Act to establish a national framework for women's health in Canada").
Meetings from the Commissioner of Lobbying of Canada. Canada does not require lobbyists to disclose what they spend, so there is no lobbying budget to report here — only the meetings they filed.